Updates from Neil Camarta – October 2, 2024

Everyone in the FSHD Community breathed a heavy sigh on September 12, 2024, when Fulcrum Therapeutics announced that its Phase 3 REACH trial did not show significant differences between the treatment and placebo groups, leading to the suspension of its development.

To help process this, we gathered our Canadian FSHD Community together for education and discussion in a virtual meeting on Wednesday, October 2nd.

Neil Camarta presented slides indicating how much is going on regarding FSHD treatments & muscle regeneration (especially here in Canada), letting people know there are still plenty of stokes in the fire these days!